Changchun High-Tech Industry Group Co 000661.SZ · CNY

Its shares trade on Shenzhen under the ticker 000661.SZ. It has been listed since 18 December 1996. In the fiscal year to 31 December 2025, it reported revenue of CN¥12.08bn and net income of CN¥155.0m. At that date it held total assets of CN¥30.08bn and shareholders' equity of CN¥22.01bn.

Changchun High & New Technology Industries (Group), Inc. engages in the research, development, production, and sale of biopharmaceuticals and proprietary Chinese medicines. The company is headquartered in Changchun, Jilin. The Company’s main products include polyethylene glycol recombinant human growth hormone injection, recombinant human growth hormone, recombinant human follicle stimulating hormone for injection, freeze-dried live attenuated varicella vaccines and rabies vaccines for human use, among other. The firm is also involved in real estate development and property management businesses. The firm operates its business mainly in domestic market.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Yuntao JiangChairman of the Board, since 2018CN¥1.1m
• Mr. Xinggong ZhuChief Financial Officer, Deputy General ManagerCN¥720,000
• Mr. Lei JinGeneral Manager, Director, since 2014
• Mr. Xiufeng LiDeputy General Manager, Director, since 2021CN¥720,000
• Mr. Zhigang WangDeputy General Manager, Director, since 2014CN¥792,000
• Mr. Peng YeDeputy General Manager, since 2021CN¥972,000
• Mr. Yan ZhangDeputy General Manager
• Mr. Hongyu LiCompany Secretary
• Mr. Yuzhi ZhangOutside DirectorCN¥72,000
• Mr. Xianchao ZhuDirectorCN¥72,000
• Mr. Chunhao LiIndependent DirectorCN¥144,000
• Ms. Chunying ZhangIndependent DirectorCN¥144,000

Overall

73

Environment

92

Social

99

Governance

29

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.